Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice

We identified all patients with chronic lymphocytic leukemia at Mayo Clinic treated with ibrutinib outside the context of a clinical trial; timing and reasons for discontinuation were ascertained, as were symptoms, exam and radiographic findings, and laboratory changes following discontinuation. Of...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Leuk Lymphoma
Κύριοι συγγραφείς: Hampel, Paul J., Ding, Wei, Call, Timothy G., Rabe, Kari G., Kenderian, Saad S., Witzig, Thomas E., Muchtar, Eli, Leis, Jose F., Chanan-Khan, Asher A., Koehler, Amber B., Fonder, Amie L., Schwager, Susan M., Slager, Susan L., Shanafelt, Tait D., Kay, Neil E., Parikh, Sameer A.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: 2019
Θέματα:
Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6813846/
https://ncbi.nlm.nih.gov/pubmed/31014142
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2019.1602268
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια